UB Paderborn / Katalog / Suche / in CDI

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Cancer discovery, 2019-12, Vol.9 (12), p.1696-1707

2019

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

Journal of medicinal chemistry, 2009-07, Vol.52 (14), p.4400-4418

2009

Link zum Volltext

Verfügbarkeit prüfen

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine

Nature chemical biology, 2011-01, Vol.7 (1), p.22

2011

Link zum Volltext

Verfügbarkeit prüfen

The Adaptor Protein Paxillin Is Essential for Normal Development in the Mouse and Is a Critical Transducer of Fibronectin Signaling

Molecular and Cellular Biology, 2002-02, Vol.22 (3), p.901-915

2002

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Rho and Rac Signaling to the Actin Cytoskeleton by Paxillin during Drosophila Development

Molecular and Cellular Biology, 2005-02, Vol.25 (3), p.979-987

2005

Link zum Volltext

Verfügbarkeit prüfen

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Cancer discovery, 2015-04, Vol.5 (4), p.424-437

2015

Link zum Volltext

Verfügbarkeit prüfen

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition

Proceedings of the National Academy of Sciences - PNAS, 2022-07, Vol.119 (27), p.1-e2200260119

2022

Link zum Volltext

Verfügbarkeit prüfen

Semisynthetic Cyclopamine Analogues as Potent and Orally Bioavailable Hedgehog Pathway Antagonists

Journal of medicinal chemistry, 2008-11, Vol.51 (21), p.6646-6649

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-324: First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-324-LB-324

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin

Journal of cell science, 1999, Vol.112 ( Pt 2) (2), p.181-190

1999

Link zum Volltext

Verfügbarkeit prüfen

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

MedChemComm, 2012-07, Vol.3 (7), p.780

2012

Link zum Volltext

Verfügbarkeit prüfen

Binary selectivity for HCV NS3/4A protease versus host proteases via irreversible inactivation at a non‐catalytic cysteine

The FASEB journal, 2010-04, Vol.24 (S1), p.907.12-907.12

2010

Link zum Volltext

Verfügbarkeit prüfen

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistanceThis article is part of the MedChemComm drug residence web themed issue.Electronic supplementary information (ESI) available. See DOI: 10.1039/c2md20017a

2012-07

Link zum Volltext

Verfügbarkeit prüfen

Protection against Anoikis and Down-regulation of Cadherin Expression by a Regulatable β-Catenin Protein

The Journal of biological chemistry, 2002-05, Vol.277 (21), p.18677-18686

2002

Link zum Volltext

Verfügbarkeit prüfen

Protection against Anoikis and Down-regulation of Cadherin Expression by a Regulatable Î²-Catenin Protein

The Journal of biological chemistry, 2002-05, Vol.277 (21), p.18677

2002

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine

The Adaptor Protein Paxillin Is Essential for Normal Development in the Mouse and Is a Critical Transducer of Fibronectin Signaling

Regulation of Rho and Rac Signaling to the Actin Cytoskeleton by Paxillin during Drosophila Development

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition

Semisynthetic Cyclopamine Analogues as Potent and Orally Bioavailable Hedgehog Pathway Antagonists

Abstract LB-324: First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma

Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Binary selectivity for HCV NS3/4A protease versus host proteases via irreversible inactivation at a non‐catalytic cysteine

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistanceThis article is part of the MedChemComm drug residence web themed issue.Electronic supplementary information (ESI) available. See DOI: 10.1039/c2md20017a

Protection against Anoikis and Down-regulation of Cadherin Expression by a Regulatable β-Catenin Protein

Protection against Anoikis and Down-regulation of Cadherin Expression by a Regulatable Î²-Catenin Protein

Suchergebnisse filtern